IAPAM Resource
Published June 18, 2026 • IAPAM Editorial Team
The non-invasive body contouring market has grown to $9.4 billion globally, but GLP-1 medications and a new generation of combination devices are fundamentally changing what patients want. Here is what aesthetic physicians need to know before adding or expanding body contouring in 2026.
In this article:
The global body contouring market reached an estimated USD 9.4 billion in 2025, up from $6.8 billion just five years ago, with projections pointing toward $15 billion by 2034. On the surface, that growth looks like a straightforward opportunity. Dig into the procedure volume data, though, and the picture is more complicated. Noninvasive fat reduction procedures dropped 40% year-over-year in 2024 — from 745,957 procedures in 2023 to 439,032 — according to the American Society of Plastic Surgeons annual report. A market that was supposed to keep accelerating is sending mixed signals.
Two forces explain that gap: the rise of GLP-1 weight loss medications and the collapse of CoolSculpting’s market dominance. For aesthetic physicians evaluating or expanding a body contouring program in 2026, understanding both is essential — because they don’t just change the device landscape, they change what patients arrive wanting in the first place.
This article covers the full picture: core technologies, current devices, updated safety data, and the practice strategy best positioned for where patient demand is actually heading.
Non-invasive body contouring encompasses a range of procedures that reduce localized fat deposits, improve skin laxity, or enhance muscle definition without incisions, anesthesia, or significant recovery time. The category spans several distinct energy-based modalities — cryolipolysis, radiofrequency, laser therapy, focused ultrasound, microwave energy, and electrical muscle stimulation — each working through different biological mechanisms to achieve overlapping aesthetic goals.
The critical framing for patient consultations: these are not weight loss procedures. The ideal non-invasive body contouring candidate is at or near their goal weight with specific areas of stubborn, diet-resistant fat or skin laxity that are disproportionate to their overall body composition. Common treatment areas include the abdomen, flanks, inner and outer thighs, arms, submental region, back, and buttocks. Patients seeking to lose 20+ pounds, or those with diffuse adiposity, are better served through medical weight management or surgical consultation before device treatments.
Compared to liposuction, non-invasive procedures offer no anesthesia requirement, no recovery downtime, no scarring, and a significantly lower per-procedure cost — trade-offs that come with modest circumferential reduction (typically 1–2 inches per treatment course) and results that develop over 3–6 months as the body processes treated tissue.
Cryolipolysis exposes fat cells to controlled cooling at temperatures that trigger apoptosis — programmed cell death — without damaging overlying skin. Fat cells are more vulnerable to cold injury than surrounding tissue, a selectivity that makes the approach work. Following treatment, apoptotic fat cells are cleared through the lymphatic system over 10–16 weeks. The FDA cleared cryolipolysis for flanks in 2010, followed by abdomen (2012), thighs (2014), submental fat (2015), and arms, back, and buttocks (2016).
The 2021 eBook noted CoolSculpting was the world’s most popular non-invasive fat reduction procedure at over 450,000 treatments annually. That dominance has since eroded significantly — both from GLP-1 competition and from growing awareness of paradoxical adipose hyperplasia (PAH), discussed in the safety section below.
RF energy heats deep tissue through electromagnetic induction, triggering fat cell apoptosis at higher energy levels and collagen remodeling/neogenesis across the dermis and subdermis. RF platforms range from bipolar configurations targeting superficial layers to monopolar systems that deliver energy to deeper tissue planes. The skin-tightening effects of RF make it particularly well-suited to patients with concurrent skin laxity — including the growing cohort of patients who have lost significant volume on GLP-1 medications. RF is used both as a standalone modality and in combination with other energy types.
Low-level or diode laser energy disrupts fat cell membranes, causing them to release their triglyceride contents without destroying the cells outright. Released lipids are cleared through the lymphatic system — which is why post-treatment movement and exercise meaningfully improve results by enhancing lymphatic flow. Newer laser fat reduction platforms use refined beam shaping technology to deliver more uniform heat distribution across tissue volumes, reducing treatment variability.
HIFU concentrates ultrasound energy at a precise focal point within subcutaneous adipose tissue, generating a rapid temperature increase that triggers fat cell death at a specific depth while leaving the dermal surface intact. Cleared fat is processed through the lymphatic system. Results develop gradually over 8–12 weeks as treated tissue is resorbed.
A newer entrant to the non-invasive fat reduction category, Coolwaves® technology uses 2.45 GHz microwave energy to selectively target fat cells and the dermis simultaneously. Unlike cryolipolysis (which cools tissue) or RF (which heats broadly), microwave energy interacts differently with fat versus water-rich tissue — a selectivity that allows for fat reduction and collagen remodeling in a single treatment without the thermal spread of conventional RF. This technology has been in use internationally for several years and recently launched in the U.S. market.
EMS and HIFEM platforms deliver electrical or focused electromagnetic energy to motor nerves, inducing supramaximal muscle contractions that are not achievable through voluntary exercise. The physiological response includes both muscle fiber hypertrophy and hyperplasia, as well as lipolysis secondary to the metabolic demand of repeated intense contractions. EMS is increasingly paired with fat reduction modalities in combination platforms — delivering body recomposition (simultaneous fat reduction and muscle building) rather than fat reduction alone. This combination approach is especially relevant for post-GLP-1 patients presenting with both residual fat and muscle atrophy from rapid weight loss. Emsculpt Neo (BTL) pioneered the combination HIFEM + RF approach in this category; PHYSIQ 360 extends it further with the addition of LZR laser fat reduction and an integrated lymphatic drainage massage handpiece.
No development has reshaped the body contouring category more than the rise of GLP-1 receptor agonists. An estimated 31 million Americans were taking GLP-1 medications — semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound) — as of late 2025. Monthly semaglutide prescriptions grew approximately 5x between 2021 and 2023. As of 2024, 72% of medical aesthetic clinics surveyed now offer GLP-1 medications as part of their service menu.
The effect on body contouring has been contradictory. For fat-reduction devices, GLP-1 adoption has been a headwind: patients redirecting discretionary budgets to monthly medication costs, combined with significant fat loss achieved through pharmacology alone, have reduced demand for CoolSculpting-style procedures. The 40% ASPS procedure drop in 2024 is partly attributable to this shift.
At the same time, GLP-1 weight loss creates a distinct set of body composition concerns that energy-based devices are well positioned to address. Patients who lose 15–30% of body weight on GLP-1 medications frequently present with loose or crepey skin, volume deflation in the face and arms, residual stubborn fat in areas resistant to overall weight loss, and muscle atrophy from the loss of lean body mass that accompanies rapid weight reduction. Body contouring consultations after GLP-1 weight loss are surging, and aesthetic firms are actively targeting this post-weight-loss segment in 2026.
For practices considering a body contouring program, the optimal strategy in 2026 is not to compete with GLP-1 medications — it is to pair with them. Offering medical weight management alongside energy-based devices for skin tightening, muscle restoration, and residual fat creates a patient journey that both categories support rather than undercut. Practices that provide medical weight management training and certification are well positioned to build this integrated offering.
On timing: patients should generally reach a stable weight for 3–6 months before initiating body contouring procedures following GLP-1 treatment. Treating patients who are still actively losing weight produces suboptimal results, as continued fat loss will alter the outcome.
PHYSIQ 360 is the direct successor to the original PHYSIQ platform, launched in April 2024, and represents a significant expansion of the combination-modality approach. The platform integrates three technologies: LZR (laser) fat reduction, electrical muscle stimulation (EMS), and proprietary STEP (Sequential Thermal & Electrical Pulse) technology that alternates between fat-burning and muscle-stimulating phases within a single session — without extending treatment time.
PHYSIQ 360’s PURE BEAM technology optimizes laser beam quality and heat delivery for more uniform fat reduction with deeper tissue penetration and higher tissue volume coverage. Up to four applicators can be programmed independently and applied simultaneously, treating multiple body areas in 15–36 minutes with no downtime. A built-in lymphatic drainage massage (LDM) handpiece — a feature unique to this platform — assists lymphatic clearance of treated fat cells following each session, which is clinically relevant for optimizing results and patient comfort post-treatment. Treatment areas include the abdomen, flanks, inner and outer thighs, rear thighs, buttocks, biceps, and triceps. The platform is explicitly designed to complement medical weight management programs, making it a natural pairing for practices offering GLP-1 protocols. No consumable time locks.
ONDA PRO brings Coolwaves® microwave technology — developed by DEKA, backed by 45+ years of laser engineering — to the U.S. and Canadian markets, launched by Cartessa Aesthetics in April 2026. The device has been in clinical use internationally and carries award recognition; its U.S. launch makes it among the newest platforms currently available to American practitioners.
ONDA PRO includes three handpieces: the Deep handpiece targets larger areas of localized fat (abdomen, flanks, thighs); the Shallow handpiece addresses cellulite and superficial skin tightening; and the Pocket handpiece focuses on submental fat, jawline definition, and smaller focal areas — extending the platform’s reach to facial contouring as well as body treatments. The double-action mechanism on both fat cells and collagen fibers in a single treatment session distinguishes it from single-modality devices.
No consumables are required, which is a meaningful practice ROI consideration compared to platforms with per-treatment applicator costs. No needles, no cryolipolysis-style suction, no significant downtime.
EVERESSE is a monopolar radiofrequency device manufactured by Classys, Inc. and distributed exclusively by Cartessa in the U.S. and Canadian markets. It is FDA-cleared and Health Canada-cleared. The platform delivers a single pulse of consistent RF energy at 6.78 MHz with continuous water cooling — a departure from multi-pulse delivery and pulsed gas cooling used in legacy monopolar RF devices, which were associated with discomfort that limited treatment intensity.
The “double depth” approach targets both the papillary and reticular dermis simultaneously, stimulating collagen generation and visible lifting and tightening. Treatments complete in under 30 minutes with no numbing required and no downtime. The device treats all skin types and over tattoos.
In August 2025, Cartessa expanded EVERESSE into full-body treatment with the addition of the S Tip — a 16.0 cm² applicator covering the abdomen, arms, legs, and buttocks. This expansion directly addresses skin laxity in areas most affected by significant weight loss, making EVERESSE the skin tightening complement to PHYSIQ 360 and ONDA PRO for post-GLP-1 body contouring. Clinical studies report over 80% patient satisfaction with improvements in skin laxity, texture, and tone. No consumable time locks.
Together, PHYSIQ 360, ONDA PRO, and EVERESSE form a three-platform Cartessa body portfolio covering fat reduction, muscle toning, cellulite, skin tightening, and submental contouring — with no consumable costs across all three devices.
CoolSculpting remains widely offered and remains an effective option for properly selected patients. However, it is no longer reasonable to present it without a substantive discussion of paradoxical adipose hyperplasia (PAH) — a complication in which treated fat cells expand and harden rather than undergoing apoptosis, producing a visible distortion of the treated area. The high-profile case of supermodel Linda Evangelista, who developed PAH following CoolSculpting procedures and settled a lawsuit against Allergan in 2022, brought widespread public awareness to the risk. Research suggests PAH may occur in approximately 1 in every 666 treatment cycles — significantly higher than the manufacturer’s historically quoted rate of 1 in 4,000. AbbVie faced ongoing litigation through 2024. Newer applicator designs have reduced PAH incidence, but the informed consent conversation is now a clinical standard for any practice offering cryolipolysis. High consumable costs per session remain a practice ROI consideration.
FDA-approved for submental fat, with off-label use for small, focal fat pockets. Kybella permanently destroys fat cell membranes through deoxycholic acid injection. Clinical trials demonstrated a 68.2% improvement rate versus 20% in the placebo group. Lower device overhead than energy-based platforms makes it accessible for practices building a body contouring program before investing in capital equipment. Significant post-treatment swelling requires patient counseling on the recovery period.
25-minute flat-applicator treatments targeting subcutaneous fat, with reported fat reduction of up to 24% per session. Multiple applicators allow simultaneous multi-area treatment. Skin tightening benefit in addition to fat reduction. Per-treatment consumable costs apply.
TruSculpt iD uses RF energy for fat reduction across larger body surface areas; consumable requirements vary by market — confirm current commercial terms with Cutera before evaluating practice ROI. TruSculpt flex uses multi-directional electrical stimulation for muscle toning and is frequently used as an adjunct to fat reduction treatments. Both are available in the U.S. market.
BTL Vanquish ME uses contactless RF for large-area fat reduction without skin contact; FDA-cleared for temporary circumferential reduction. Morpheus8 Body (InMode) combines RF microneedling for skin tightening and subdermal fat remodeling, including application in post-weight-loss skin laxity cases. Both are available in the U.S. market.
| Device | Technology | Fat Reduction | Muscle Toning | Skin Tightening | Post-GLP-1 | Consumables |
|---|---|---|---|---|---|---|
| PHYSIQ 360 (Cartessa) | LZR + EMS + STEP | ✓ | ✓ | Moderate | ✓ | No |
| ONDA PRO (Cartessa) | Coolwaves® Microwave | ✓ | — | ✓ | ✓ | No |
| EVERESSE (Cartessa) | Monopolar RF | — | — | ✓ (excellent) | ✓ (laxity) | No |
| CoolSculpting | Cryolipolysis | ✓ | — | Moderate | Limited | Yes |
| Kybella | Deoxycholic Acid | ✓ (small) | — | Moderate | Limited | N/A |
| SculpSure | 1060nm Laser | ✓ (24%) | — | ✓ | Limited | Yes |
| TruSculpt iD | RF | ✓ | — | ✓ | ✓ | Verify* |
| TruSculpt flex | EMS | — | ✓ | — | ✓ (muscle) | Verify* |
| BTL Vanquish ME | Contactless RF | ✓ | — | Moderate | Limited | No |
| Morpheus8 Body | RF Microneedling | Moderate | — | ✓ | ✓ (laxity) | Yes |
LZR Laser + EMS + STEP
✓ Fat Reduction✓ Muscle ToningModerate Skin✓ Post-GLP-1No consumables
Coolwaves® Microwave
✓ Fat Reduction✓ Skin Tightening✓ Post-GLP-1No consumables
Monopolar RF
✓ Skin Tightening✓ Post-GLP-1 (laxity)No consumables
Cryolipolysis
✓ Fat ReductionModerate SkinLimited Post-GLP-1Consumables required
Deoxycholic Acid
✓ Fat (small areas)Moderate SkinLimited Post-GLP-1Injectable — no device cost
1060nm Laser
✓ Fat Reduction (24%)✓ Skin TighteningLimited Post-GLP-1Consumables required
RF
✓ Fat Reduction✓ Skin Tightening✓ Post-GLP-1Consumables — verify with Cutera*
EMS
✓ Muscle Toning✓ Post-GLP-1 (muscle)Consumables — verify with Cutera*
Contactless RF
✓ Fat ReductionModerate SkinLimited Post-GLP-1No consumables
RF Microneedling
Moderate Fat✓ Skin Tightening✓ Post-GLP-1 (laxity)Consumables required
*TruSculpt consumable requirements vary by market; confirm current commercial terms with Cutera.
The American Society of Plastic Surgeons recommends liposuction for patients seeking larger-volume fat removal. Non-invasive procedures are optimized for patients pursuing 1–2 inch circumferential reduction — enough for clothing to fit differently and for treated areas to feel more proportionate, without the risks, recovery, and cost of surgery.
Results timelines vary by modality. Laser and RF-based treatments typically produce visible changes within 10–14 days, with full results at 2–3 months. Cryolipolysis results develop more slowly, with full effect at 3–6 months as the body clears apoptotic fat. Patients who gain weight after treatment will accumulate new fat in the treated areas, so body weight stability is a prerequisite for durable outcomes. Clear expectation-setting at consultation directly determines patient satisfaction.
Regardless of modality, treated fat follows the same physiological pathway. Apoptotic fat cells break down and release triglycerides, which are packaged into lipoproteins, transported through the lymphatic system, and metabolized by the liver. The process is gradual — typically 8–16 weeks depending on the treatment type, lymphatic function, and the patient’s metabolic rate.
For laser-based and HIFU treatments, where fat cell membranes are disrupted and fatty acids are released into the interstitium, post-treatment physical activity meaningfully accelerates clearance. Patients should be instructed to maintain regular cardiovascular exercise in the weeks following treatment. For cryolipolysis, the apoptotic process is slower and less dependent on immediate lymphatic clearance.
Body weight must remain stable. Non-invasive fat reduction reduces the number of fat cells in treated areas — but remaining fat cells throughout the body will expand if caloric intake exceeds expenditure, depositing fat in untreated regions.
In 2023, the FDA published guidance noting that noninvasive body contouring technologies are not risk-free and their results may only be temporary — a calibration worth incorporating into patient education materials. The agency’s position reinforces what evidence-based practitioners should already be communicating: these are elective medical procedures with genuine risks, not guaranteed outcomes, and lifestyle factors significantly influence results.
For cryolipolysis specifically, PAH is the risk that has most changed clinical practice. Informed consent should include discussion of PAH incidence (approximately 1 in 666 treatment cycles per available research), what PAH looks and feels like, and what corrective options exist (liposuction is the primary treatment). Practitioners should be familiar with updated applicator designs that have reduced PAH risk, but should not present any rate as negligible given the severity of the outcome when it occurs.
Standard contraindications across non-invasive platforms include BMI significantly outside the ideal candidate range, pregnancy, active malignancy in the treatment area, certain implanted electronic or metallic devices, and conditions affecting skin sensation or healing. Combination platforms require review of modality-specific contraindications for each energy type used. All non-invasive body contouring procedures produce best results as part of an overall approach to body composition — not as standalone interventions absent lifestyle management.
The market math for body contouring remains compelling: a $9.4 billion global market growing to a projected $15 billion by 2034, with a post-GLP-1 patient segment actively seeking skin tightening, muscle restoration, and residual fat reduction at volumes that are accelerating rather than plateauing. The practices best positioned for this market are those that can serve the full arc of the GLP-1 patient journey — weight loss, body recomposition, and skin quality — rather than offering device-only treatments in isolation.
Demographically, Gen X currently represents the largest spending cohort in non-invasive aesthetic procedures, with Millennial spend growing rapidly. Both groups are well represented in the GLP-1 patient population.
From a device portfolio standpoint, the most defensible 2026 body contouring program covers three distinct clinical needs: fat reduction, skin tightening, and muscle toning. A three-platform combination — such as PHYSIQ 360 for fat reduction and muscle toning, ONDA PRO for cellulite and combined fat/skin treatment, and EVERESSE for targeted skin tightening — covers all three with no consumable costs across the portfolio. No-consumable platforms also reduce per-treatment overhead and simplify break-even analysis, which matters when making a capital allocation case internally.
Patient financing is worth building into the conversation: per-session costs for non-invasive body contouring range from a few hundred dollars for injectable treatments to $1,000 or more for multi-area device sessions, and offering financing through a third-party platform removes cost as a barrier to treatment acceptance and extends the practice’s patient reach. For practices not yet offering GLP-1 medical weight management, this is the complementary revenue stream that transforms a device program into a patient journey. IAPAM’s Certified Medical Weight Management Provider program provides the clinical foundation and protocols to offer GLP-1 weight loss alongside a body contouring device portfolio. For aesthetic physicians building or expanding a non-invasive body contouring program, the Aesthetic Medicine Symposium in Scottsdale, AZ provides hands-on training and device exposure to evaluate current platforms firsthand.
IAPAM Training
Pair Medical Weight Management with a Device Portfolio
IAPAM offers two complementary programs for physicians building a body contouring practice. Add GLP-1 medical weight management to create the full patient journey — or get hands-on device exposure at the Scottsdale Symposium.